The Fort Worth Press - European medicines watchdog rejects new Alzheimer's drug

USD -
AED 3.672505
AFN 64.49673
ALL 82.158918
AMD 358.939509
ANG 1.790403
AOA 916.999919
ARS 1564.860712
AUD 1.50025
AWG 1.8
AZN 1.700353
BAM 1.784033
BBD 2.019539
BDT 124.712665
BGN 1.77347
BHD 0.378367
BIF 3011.780588
BMD 1
BND 1.292991
BOB 11.787135
BRL 5.929501
BSD 1.002654
BTN 93.493996
BWP 14.163223
BYN 2.998481
BYR 19600
BZD 2.01662
CAD 1.43229
CDF 2280.000149
CHF 0.842945
CLF 0.025791
CLP 1015.079814
CNY 6.66665
CNH 6.67819
COP 3430.58
CRC 448.877578
CUC 1
CUP 24.064252
CVE 100.580597
CZK 22.29135
DJF 178.556769
DKK 6.81587
DOP 60.358117
DZD 137.168807
EGP 53.808499
ERN 15
ETB 164.575067
EUR 0.91186
FJD 2.292598
FKP 0.762556
GBP 0.763145
GEL 2.594977
GGP 0.762556
GHS 11.787081
GIP 0.762556
GMD 73.999939
GNF 8888.99024
GTQ 7.66589
GYD 209.71832
HKD 7.839502
HNL 26.953635
HRK 6.831965
HTG 131.457369
HUF 339.622503
IDR 18294.55
ILS 3.33015
IMP 0.762556
INR 92.722249
IQD 1520.092309
IRR 1937314.502631
ISK 125.109553
JEP 0.762556
JMD 158.691934
JOD 0.70896
JPY 158.9995
KES 130.059924
KGS 87.450193
KHR 4080.068959
KMF 448.999551
KPW 900.00035
KRW 1336.301234
KWD 0.31158
KYD 0.835644
KZT 451.435765
LAK 22592.768271
LBP 89796.128726
LKR 333.755975
LRD 168.449186
LSL 17.274601
LTL 2.95274
LVL 0.60489
LYD 6.489159
MAD 9.971905
MDL 18.399496
MGA 4527.086811
MKD 56.124496
MMK 2099.807194
MNT 3607.161117
MOP 8.102142
MRU 40.900654
MUR 46.780059
MVR 15.410223
MWK 1738.682283
MXN 19.082765
MYR 4.113699
MZN 63.91013
NAD 17.27405
NGN 1352.490221
NIO 36.896835
NOK 9.782355
NPR 149.590893
NZD 1.818601
OMR 0.384487
PAB 1.002755
PEN 3.42148
PGK 4.510668
PHP 63.881067
PKR 277.171369
PLN 4.05793
PYG 6286.657727
QAR 3.645038
RON 4.880398
RSD 107.266023
RUB 82.02575
RWF 1484.005145
SAR 3.751725
SBD 8.130619
SCR 13.848637
SDG 601.511051
SEK 10.202805
SGD 1.290255
SHP 0.760572
SLE 22.797529
SLL 20969.503664
SOS 573.031402
SRD 37.359778
STD 20697.981008
STN 22.348407
SVC 8.773306
SYP 13002.000337
SZL 17.270065
THB 33.939468
TJS 9.224798
TMT 3.51
TND 3.038261
TOP 2.40776
TRY 50.5779
TTD 6.803701
TWD 32.985978
TZS 2669.182985
UAH 45.169709
UGX 4246.158618
UYU 40.700724
UZS 12012.442077
VES 917.61775
VND 25793
VUV 121.154187
WST 2.823282
XAF 598.14091
XAG 0.023513
XAU 0.000279096509
XCD 2.70255
XCG 1.807054
XDR 0.707052
XOF 598.14091
XPF 108.786077
YER 236.550191
ZAR 17.48671
ZMK 9001.191204
ZMW 20.605862
ZWL 321.999592
SSP 5782.645223
MXV 2.139117
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

European medicines watchdog rejects new Alzheimer's drug
European medicines watchdog rejects new Alzheimer's drug / Photo: © ANP/AFP

European medicines watchdog rejects new Alzheimer's drug

Europe's medicines watchdog on Friday rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits.

Text size:

The decision by the Amsterdam-based European Medicines Agency was met with dismay, but experts said effective treatment for the degenerative mental disease affecting millions in Europe alone, was getting closer.

"The CHMP recommended not granting a marketing authorisation for Leqembi, a medicine intended for the treatment of Alzheimer's disease," the European Medicines Agency said, referring to its committee for evaluating drugs for human use.

Leqembi, which was developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.

But the CHMP said "the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine."

"The most important safety concern with Leqembi is the frequent occurrence of amyloid-related imaging abnormalities (ARIA), a side effect, seen in brain imaging, that involves swelling and potential bleedings in the brain," the EMA said.

- 'Unmet need' -

Leqembi is a monoclonal antibody, a type of protein that clings to a substance in the brain and can delay worsening of the disease. It is given intravenously every two weeks.

Leqembi, together with another Alzheimer's drug called Aduhelm -- also developed by Biogen and Eisai -- received approval from the US Food and Drug Administration (FDA) early last year.

Both drugs were approved through an accelerated process by the FDA for drugs treating serious conditions where there is an unmet medical need.

But in late January this year, Biogen pulled the controversial Aduhelm from the market, saying it was focusing on Leqembi instead.

Preliminary data from a trial of Leqembi was released in September 2022 and found it slowed cognitive decline in Alzheimer's patients by 27 percent.

Around eight million people in the European Union live with dementia, with Alzheimer's disease accounting for more than half of these cases, according to the Alzheimer Europe website.

Eisai, in a statement, said it was "extremely disappointed with the CHMP's negative opinion".

"There is a significant unmet need for new innovative treatment options that target an underlying cause of disease progression," Eisai's chief clinical officer Lynn Kramer said.

Eisai said it would seek a re-examination of the EMA's opinion "to ensure this treatment is available for eligible people living with early Alzheimer's disease in the EU as soon as possible."

The EMA said Eisai presented a main study involving 1,795 people with early Alzheimer's who either received Leqembi or a placebo, measured over a span of 18 months.

Eisai said that the watchdog added that its refusal had "no consequences for patients in clinical trials with Leqembi".

Eisai may now ask for a re-examination within 15 days, the EMA said.

- 'Ramp up efforts' -

Experts voiced disappointment at the EMA's refusal, but added there were "reasons to remain hopeful".

"Lecanemab has shown that it is possible to slow down disease progression, and research does work," said Tara Spires-Jones, president of the British Neuroscience Association.

"Now we need to ramp up our efforts to discover new and safer treatments," she said in a statement, adding that "each discovery brings us closer to new and better treatments."

Bart De Strooper, a professor in Alzheimer's disease at the University College London called the EMA's decision "unfortunate yet not unexpected".

"This conservative approach means that patients and doctors eager to explore a proven effective drug are now denied access," he said in a statement.

"With no current therapies available, it's disheartening to think that if we had applied such caution in the past, particularly with cancer drugs and their severe side effects, we might still be without cancer treatments today," De Strooper said.

J.M.Ellis--TFWP